[Use of metabolic bone markers in clinical setting].
It is useful to effectively measure metabolic bone markers for choice of pharmaceutical agents and early assessment of treatment efficacy in osteoporosis. The measurements of markers for bone resorption related to type I collagen crosslinks are recommended in evaluating treatment efficacy of bisphosphonates (BPs). Since the changes in free crosslinks during treatments with newer BPs containing amino residues is subtle, the advantage of measurement of N-telopeptide (NTX) has been reported elsewhere. When the change in bone markers exceed the magnitude of the least significant change, treatment efficacy is confirmed in individual patients.